ArticleCancers2026
Cystic Renal Masses: From Malignancy Probability to Risk-Adapted Management.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cystic renal masses (CRMs) encompass a broad spectrum of conditions ranging from simple renal cysts to cystic renal cell carcinoma. Their detection has increased markedly with the widespread use of abdominal imaging, raising concern about potential overtreatment: many complex CRMs treated surgically are ultimately benign, while some malignant lesions are low grade, localized, and follow a relatively indolent clinical course. Although the Bosniak classification stratifies malignancy probability, translating lesion characteristics into preoperative assessments of biological aggressiveness and patient-specific clinical consequences remains challenging. Drawing on published evidence and common clinical decision-making scenarios, this Perspective outlines the pathologic classification of CRMs, examines the limitations of the Bosniak classification, and discusses the prospects for and current barriers to the use of radiomics and artificial intelligence for benign-versus-malignant classification. With the dual objectives of differentiating benign from malignant lesions and assessing biological aggressiveness, we focus on individualized management strategies that integrate the probability of malignancy, potential clinical harm, and patient-specific factors. These strategies include conservative management, indications for surgery, and selection of surgical approach. The aim is to inform more standardized and precise diagnosis and management of CRMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.